ClinicalTrials.gg
RecruitingNCT07241910Updated Jun 8, 2026

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061

A Phase 1 interventional study of SYH2061 and Placebo in Healthy Subjects, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, single-ascending dose study in healthy subjects to evaluate the safety, tolerability, PK, and PD of SYH2061.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. is the lead sponsor of 30 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be informed of the study before it begins, fully understand the study content, procedures, and potential adverse reactions, and voluntarily sign the written ICF;
  2. Healthy male or female subjects, aged 18 to 55 years (inclusive);
  3. ranging from 19.0 to 28.0 kg/m2 (inclusive), with a body weight of ≥ 50 kg for males and ≥ 45 kg for females;
  4. The results of various examinations, such as physical examination, vital signs, , chest X-ray, abdominal B-scan ultrasound, and laboratory tests at screening are normal or abnormal without clinical significance;
  5. Vaccinated against meningococcal ACYW135 vaccine and pneumococcal vaccine at least 14 days prior to the first dose, or have valid documentation of receiving the respective vaccinations within the past 3 years prior to dosing as evaluated by the investigator.;
  6. Subjects and their partners agree to use effective and reliable methods from 14 days before signing the ICF until 6 months after drug administration; male subjects agree not to donate sperm and female subjects agree not to donate ova from signing the ICF until 6 months after study drug administration;
  7. Subjects are able to communicate well with the investigator and can complete the study in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. History and/or current presence of medical conditions, including but not limited to circulatory system disorders, hematological or hematopoietic system disorders, respiratory disorders, endocrine disorders, urinary system disorders, digestive system disorders, neurological or psychiatric disorders, diseases, malignant tumors, severe trauma, or any other disease that should be excluded or may interfere with the interpretation of the study results in the opinion of the investigator;
  2. History of splenectomy, or functional or anatomical asplenia;
  3. Known or suspected hereditary or acquired complement deficiency or impaired complement activity, or complement activity below the normal range at screening;
  4. History of meningococcal infection, or positive Neisseria meningitides test at screening;
  5. Subjects who are frequently exposed to Neisseria meningitides (e.g., research, industrial, or clinical laboratory personnel, military personnel during recruit training, daycare center staff, etc.), and those who have traveled to or plan to travel to endemic areas for meningococcal meningitis (e.g., India, sub-Saharan Africa, Saudi Arabia) within 6 months before dosing or during the course of the study;
  6. History of recurrent or chronic infections (e.g., recurrent upper respiratory tract infection, diarrhoea, etc.) or infections requiring systemic antibiotic therapy within 3 months before dosing;
  7. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection including herpes, herpes zoster, or cold sores within 14 days before dosing;
  8. History or current presence of latent or active pulmonary tuberculosis, or positive T-SPOT test at screening;
  9. History of major surgery within 6 months prior to screening, or plan to undergo major surgery during the course of the study;
  10. Subjects with severe allergic diseases or allergic constitution (≥ 3 drug or food allergies), or a known history of allergy to the drug components, oligonucleotide drugs, or vaccinations;
  11. Subjects who are allergic to β-lactam antibiotics (e.g., penicillin, cephalosporins) or ciprofloxacin, or have any , or unwilling to use antibiotic prophylaxis as specified in the protocol;
  12. Intolerance to subcutaneous injection, or presence of abdominal scars (from surgery, burns, etc.) that affect subcutaneous administration, and any skin abnormalities and/or tattoos that may affect the safety assessment of the injection site;
  13. Any of the following liver function test results: (ALT), aspartate aminotransferase (AST), total (TBIL), γ-glutamyl transferase (GGT), or alkaline phosphatase (ALP) above the at screening;
  14. Estimated (eGFR) \< 90 mL/min/1.73 m2 (calculated by the simplified MDRD formula) at screening;
  15. Prolonged /QTc interval at screening or baseline (QTcF > 450 ms for males, > 470 ms for females);
  16. Positive result for any of the following: surface antigen (HBsAg), virus antibody, (HIV) antigen/antibody, or Treponema pallidum antibody;
  17. Use of any prescription drugs, over-the-counter drugs, herbal medicines or vitamin and dietary supplements within 14 days or 5 half-lives (whichever is longer) before dosing;
  18. Received complement inhibitor treatment (e.g., Eculizumab, Crovalimab, etc.) within 6 months or 5 half-lives (whichever is longer) before dosing;
  19. Received live or within 28 days before dosing, or plan to receive such vaccines during the course of the study (except for vaccinations planned by the study protocol);
  20. Blood loss or blood donation of more than 200 mL within 3 months before screening (except for menstruation in females), or donation within 2 weeks before screening;
  21. History of drug abuse, or use of illicit drugs within 3 months before screening, or habitual use of any psychotropic drugs (including herbal medicines), or a positive urine drug screen;
  22. Regular alcohol consumption within 6 months before screening, defined as weekly alcohol consumption exceeding 14 units (1 unit = 360 mL of 5% alcohol beer or 45 mL of 40% alcohol spirits or 150 mL of 12% alcohol wine), or inability to stop alcohol intake as required by the protocol during the study, or a positive blood alcohol test;
  23. Average daily smoking of more than 5 cigarettes (or an equivalent amount of tobacco in e-cigarettes) within 3 months before screening, or unwilling to avoid using any tobacco products as required by the protocol during the study;
  24. Participation in any clinical trial within 3 months before screening (or within 12 months before screening for oligonucleotide drugs)
  25. In addition to the above requirements, female subjects who meet the following criteria should also be excluded: a. Pregnant or lactating women; b. Use of oral within 28 days prior to screening; c. Use of long-acting estrogen and/or progesterone injections and/or implants within 6 months prior to screening; d. females of who had unprotected sexual intercourse with their partner within 28 days prior to dosing.
  26. Any other conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    SYH2061 group

    Subjects in experimental group will receive a single subcutaneous injection of SYH2061 on Day 1.

    Drug: SYH2061

  • Placebo comparator
    Placebo group

    Subjects in placebo group will receive a single subcutaneous injection of placebo on Day 1.

    Drug: Placebo

Interventions

  • DrugSYH2061

    subcutaneous injection

  • DrugPlacebo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Subjects with Adverse Events as Assessed by CTCAE v5.0

    To assess the safety and tolerability of SYH2061 in healthy subjects

    Time frame: Up to Day 337

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of SYH2061

    To characterize the Cmax of SYH2061 in healthy subjects

    Time frame: Up to 72 hours post-dose

  2. Time to maximum observed plasma concentration (Tmax) of SYH2061

    To characterize the Tmax of SYH2061 in healthy subjects

    Time frame: Up to 72 hours post-dose

  3. Area under the concentration-curve from zero to the last quantifiable concentration (AUClast) of SYH2061

    To characterize the AUClast of SYH2061 in healthy subjects

    Time frame: Up to 72 hours post-dose

  4. Area under the concentration-time curve from zero to infinity (AUCinf) of SYH2061

    To characterize the AUCinf of SYH2061 in healthy subjects

    Time frame: Up to 72 hours post-dose

  5. Terminal elimination half-life (t1/2) of SYH2061

    To characterize the t1/2 of SYH2061 in healthy subjects

    Time frame: Up to 72 hours post-dose

  6. Apparent clearance (CL/F) of SYH2061

    To characterize the CL/F of SYH2061 in healthy subjects

    Time frame: Up to 72 hours post-dose

  7. Apparent volume of distribution (Vz/F) of SYH2061

    To characterize the Vz/F of SYH2061 in healthy subjects

    Time frame: Up to 72 hours post-dose

  8. Percent change from baseline in complement C5 and its fragments C5a and C5b-9

    To assess the PD effects of SYH2061 in healthy subjects

    Time frame: Up to Day 337

  9. Percent change from baseline in complement alternative pathway (CAP)

    To assess the PD effects of SYH2061 in healthy subjects

    Time frame: Up to Day 337

  10. Percent change from baseline in complement classical pathway (CCP)

    To assess the PD effects of SYH2061 in healthy subjects

    Time frame: Up to Day 337

  11. Incidence of ADA

    To assess the immunogenicity of SYH2061 in healthy subjects

    Time frame: Day85

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Dec 23, 2025
Primary completionEst.
Nov 24, 2026
CompletionEst.
Apr 1, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07241910
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Dec 23, 2025
Primary completion
Nov 24, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
+86-0311-69085587
Wei Hu
Contact
huwei@ahmu.edu.com
13856086475

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion